Ontology highlight
ABSTRACT: Background
Buprenorphine treatment has been associated with reduced non-prescribed opioid use and opioid related overdose (OD). We evaluated initial outcomes of rapid induction onto extended-release injectable buprenorphine (BUP-XR) within 7 days of emergency department presentation for unintentional OD.Methods
Between February 2019-February 2021, N = 19 patients with opioid use disorder received buprenorphine/naloxone (4/1 mg), followed by BUP-XR (300 mg) at induction and continued BUP-XR outpatient for 6 months. Primary outcomes included adverse events, repeat OD, and death.Results
For patients who received at least one dose of BUP-XR, there were no treatment related serious adverse events or symptoms of precipitated withdrawal. In addition, there were no repeat visits for ODs or deaths within 6 months of the initial OD.Discussion
These preliminary findings support the need for larger controlled clinical trials to examine the safety and efficacy of rapid induction of BUP-XR in patients with opioid use disorder at high risk of opioid OD. Rapid induction onto long-lasting injectable buprenorphine may be a promising and protective treatment approach in the future.
SUBMITTER: Ochalek TA
PROVIDER: S-EPMC10073633 | biostudies-literature | 2023 Jun
REPOSITORIES: biostudies-literature
Ochalek Taylor A TA Ringwood Katy J KJ Davis Theresa T TT Gal Tamas S TS Wills Brandon K BK Sabo Roy T RT Keyser-Marcus Lori L Martin Caitlin E CE Polak Kathryn K Cumpston Kirk L KL Moeller F Gerard FG
Drug and alcohol dependence reports 20230316
<h4>Background</h4>Buprenorphine treatment has been associated with reduced non-prescribed opioid use and opioid related overdose (OD). We evaluated initial outcomes of rapid induction onto extended-release injectable buprenorphine (BUP-XR) within 7 days of emergency department presentation for unintentional OD.<h4>Methods</h4>Between February 2019-February 2021, <i>N</i> = 19 patients with opioid use disorder received buprenorphine/naloxone (4/1 mg), followed by BUP-XR (300 mg) at induction and ...[more]